Ranibizumab found to have no effect on vessel diameter in certain patients
Terai and colleagues reported in the Journal of Retinal and Vitreous Diseases that intravitreal ranibizumab did not significantly affect retinal vessel diameter in patients with diabetic macular edema.
The abstract explained that study included 14 men and 16 women with a mean age of 60 years diagnosed with diabetic macular edema.
Treatment comprised three intravitreal injections of ranibizumab given at 4-week intervals. Examinations were conducted before the first or baseline, before the second, before the third injection and 3 months after baseline.
Measured parameters included blood pressure, static retinal vessel analysis and dynamic retinal vessel analysis, measured by the change in vessel diameter in response to flicker simulation during three measurement cycles.
The researchers found that the reduction of the central retinal artery was shown to be statistically insignificant. In addition, central retinal vein equivalent was reduced to a point revealing no statistically significant differences between examination time points.
Terai and colleagues concluded that intravitreally applied ranibizumab did not significantly affect retinal diameter in patients with diabetic macular edema. Decline in the central foveal thickness after ranibizumab therapy, as measured by spectral domain optical coherence tomography, was not linked to any change in retinal vessel diameter or dilatatory response, neither for the arterioles nor venules.